Table IV.
Multivariate Cox analysis of PFS and OS.
| Multivariate analysis | ||||
|---|---|---|---|---|
| Variables | Groups | HR (95% CI) | P-value | Adjusted P-value |
| OS (n=64) | ||||
| CRP, mg/l | >10 vs. ≤10 | 6.48 (2.11–19.91) | 0.001 | 0.004 |
| Smoking | Yes vs. no | 2.87 (1.18–6.96) | 0.020 | 0.020 |
| HLA-Bw4T8 | Positive vs. negative | 3.58 (1.51–8.47) | 0.004 | 0.012 |
| KIR2DS4del mRNA | Positive vs. negative | 3.33 (1.39–7.94) | 0.007 | 0.014 |
| PFS (n=64) | ||||
| CRP, mg/l | >10 vs. ≤10 | 2.94 (1.36–6.37) | 0.006 | 0.054 |
| Histology | SCC vs. AD | 2.38 (0.95–5.95) | 0.065 | 0.195 |
| Gender | Male vs. female | 1.71 (0.84–3.49) | 0.138 | 0.204 |
| ECOG PS | 2 vs. 0 | 4.20 (1.10–16.09) | 0.036 | 0.160 |
| HLA-Bw4T8 | Positive vs. negative | 2.41 (1.21–4.83) | 0.013 | 0.091 |
| KIR2DS1 DNA | Positive vs. negative | 17.08 (1.28–227.54) | 0.032 | 0.160 |
| KIR2DL5all DNA | Positive vs. negative | 34.14 (1.52–765.94) | 0.026 | 0.156 |
| KIR2DL5A DNA | Positive vs. negative | 0.047 (0.005–0.461) | 0.047 | 0.072 |
| KIR2DL5B DNA | Positive vs. negative | 0.063 (0.002–1.737) | 0.063 | 0.204 |
Bold print, P-values indicating statistically significant differences. OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval-; CRP, C-reactive protein; SCC, squamous cell carcinoma; AD, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; KIR, killer-cell immunoglobulin-like receptor; HLA, human leukocyte antigen.